Morgan Stanley and Wells Fargo maintained 'Buy' ratings for Jazz Pharmaceuticals, citing benefits from tariffs and onshoring trends for AI stocks.
5 reports, 2 independent
Updated Aug 4
Gone quiet
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley and Wells Fargo maintained 'Buy' ratings for Jazz Pharmaceuticals, citing benefits from tariffs and onshoring trends for AI stocks.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Morgan Stanley reissued an overweight rating on Jazz Pharmaceuticals.1 source
Banks maintained 'Buy' ratings for Jazz Pharmaceuticals, citing tariffs and onshoring benefits for AI stocks.1 source
- Cramer discussed WFC's valuation and restrictions regarding AI stocks benefiting from Trump tariffs.
Keep exploring
The entities involved
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
-
Morgan Stanley
U.S. investment bank
-
Wells Fargo
American multinational banking and financial services company
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- Goldman Sachs and Zeta Interactive noted that tariffs and onshoring benefit AI stocks, citing accelerated Q2 growth and raising price targets.
- Tariffs and onshoring trends may benefit AI stocks, with energy infrastructure like Kinder Morgan noting that they transport 40% of the natural gas produced in the US.
- Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.
- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.
Coverage
Newest first; wire copies grouped- tickerreport.com
- Insider MonkeyMorgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains ‘Buy’ Rating Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is included in our list of the 10 Most Undervalued Foreig
- Unknown outlet